Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares are surging Thursday afternoon following an intellectual property milestone.
- Creative Medical Tech stock is showing exceptional strength. What’s fueling CELZ momentum?
Broadening IP Protection for Cell-Free Exosome Technology
The clinical-stage biotechnology firm announced it received a Notice of Allowance from the USPTO for its patent application titled “Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells.”
Once issued, the company says the new patent strengthens protection around Creative Medical’s MyeloCelz platform. Creative Medical says the cell-free technology utilizes stem-cell-programmed myeloid cells to induce immune tolerance and stop the autoimmune destruction of insulin-producing pancreatic beta cells.
This addition builds on a portfolio of roughly 60 issued patents and pending applications.
Management Commentary and Market Potential
“Each new Notice of Allowance adds another layer of protection around the core biology that differentiates our platform,” stated Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “Building overlapping IP protection across both our cellular and cell-free diabetes programs is a deliberate strategy to maximize the long-term value of our platform for patients and shareholders alike.”
CELZ Shares Surge Thursday Afternoon
CELZ Price Action: Creative Medical Tech shares were up 104.67% at $1.36 at the time of publication on Thursday, according to Benzinga Pro data.
Image: Shutterstock